LIVEWIRE ERGOGENICS, INC. UNVEILS NEW CANNABIS SPECIFIC STRATEGY 
TO ACCELERATE GROWTH AND ENHANCE VALUE
 

  Livewire CEO Outlines Company's Core Business Strategy
Anaheim, CA July 13, 2017 - LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, today provides a brief outline of its most current developments and the progression of its core business strategies. The company is also proud to announce its new branding and corporate website located at www.LiveWireErgogenics.com.

“We are confident that the strategy presented today is the best way to capture momentum in the cannabis market, while increasing value for our shareholders. Each initiative laid out below represent solid blocks in a strong foundation that allows us to build a company with clear direction and focus,” said LiveWire Ergogenics CEO Bill Hodson.

Current Filing Status
The Company expects to have its Financial Reports for Q1 2017 completed and posted within the next several days. The posting of this quarter will bring the company to a “current” status on OTC Markets Pink and the Stop Sign will be subsequently removed. The Company’s management will assure that all future filings will be made accordingly to maintain a “current” status.

Claim a Cannabis Market Stake
LiveWire has assembled a team of innovators to aggressively proceed with research and development to capture market share. The Company has entered into several strategic alliances and business consulting agreements with horticulturists, extractors, distributors, laboratories, branding agencies and body care specialists. LiveWire intends to utilize the wealth of the team’s experience to acquire and/or develop new product offerings by way of this talented network of professionals in its quest for breakthrough success.

It Starts With the Clone
Our experts have over 25 years of combined experience in this fascinating field and have assembled a massive genetics library, now available to LiveWire.  This specialty has high barriers to entry when considering the scientific knowledge required to cultivate and propagate plants, and to understand the complex techniques to study and produce new generations of desirable strains. The Company understands new technologies are rapidly approaching, and exploring new advances in cloning techniques such as tissue culture cultivation, is paramount. The near-term plan is to support and guide the efforts of our experts into a legal, profitable and sustainable business model with a long-term goal of expanding nationally.

Continues With Research
Livewire is planning to commence with research studies to explore the application of cannabinoid-based products to target specific ailments or conditions with a large “sufferer” population. These small research studies are designed to document safety, dosage and efficacy of various combinations of CBD/THC and terpene profiles. The Company has established two independent research teams with highly recognized and published experts in their respective fields. In addition to these projects, LiveWire has begun development for products in the sports and cosmetics markets. Livewire’s topical creams currently being tested are infused with different dosage combinations of fragrances and herbs along with THC and CBD, and are being developed for licensing. Additional research groups from several disciplines are currently being assembled.

Sustaining the Edible Market
LiveWire has been in the energy chew business for over eight years, and we will continue to sell our existing line, as well as a new all-natural line of caffeinated bite-sized energy chews.  In addition, the company is exploring the utilization of these chews as a dosing supplement for medical and recreational CBD and THC. Our proprietary cold manufacturing process makes the chew matrix a perfect medium for edibles where the integrity of the ingredients is of high importance.

LiveWire’s Proprietary Verification System
A credible certification process is crucial in the high-growth and unruly medical cannabis industry. LiveWire has developed a proprietary “7xPure Compliance & Dosage Verification System”. The 7xPure system is an assembled set of verified documents pertaining to compliance and dosage claims and the assignment of a lot-code relating to the sum of seven highly scrutinized parts.  In order for a product to receive the 7xPure Verification Seal, it must prove dosage claims, label claims, manufacturing good practices, microbiological and residual solvent testing and much more. All products produced by LiveWire will meet the criteria necessary to display the 7xPure verification seal. The company will also market its 7xPure Verification System to all companies in the industry, aiming to make it the “Gold Standard” in the industry for the benefit of all consumers.

Stacking the Board
The Company will expand its Board of Directors and Advisory Board beyond the scope of the currently participating research experts. It is in discussion with experts in the cannabis industry, as well as doctors, bio-chemists, real estate, legal, and financial leaders. Our intent is to have world-class experts in various fields in which their knowledge and experience will be one of the driving factors for future success.

Communicating its Message
LiveWire will provide transparency and consistency with in-depth shareholder communications. The Company is committed to frequently updating the public about its new and material developments along with maintaining all required filings on OTC Markets Pink. In addition to the company’s required communications, LiveWire has entered into a consulting agreement with a renowned financial research firm to prepare an in-depth research report for public dissemination, once all OTC filings have been brought current.

About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) is focused on identifying and monetizing current and future trends in the health and wellness industry. This will be accomplished by way of research partnerships for specific ailments, cloning of cannabis strains to produce positive medicinal results, dosing verification of zero pesticide products for quality brands, development and commercialization of cannabinoid based products and services. The team at LiveWire Ergogenics is committed to developing great products and generate innovative ideas for the future of the company and the industry.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for future operations, the development, regulatory approvals and commercialization of the Company’s products, or any of the Company’s other proposed products, systems or services. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and actual events may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, the Company’s inability to obtain additional financing, delays in the development of its products, the impact of significant government regulation in the cannabis industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure in general to implement the Company’s business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.
LIVEWIRE ERGOGENICS INC.
1600 North Kraemer Blvd.
Anaheim, CA 92806
714-740-5144
www.livewireenergy.com
[email protected]
INVESTOR CONTACT
EquiNet, LLC
Toll Free: (877) 964-6463
Direct: (858) 264-6500
If you want to follow all other companies that we cover with more in depth research reports, go to our research site at www.swiresearch.com/report-index to download the reports,
or visit
www.stockwatchindex.com for up to date news on the covered companies.
Please feel free to
re-distribute the reports to your friends and colleagues.
S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has been compensated with restricted shares  for the dissemination of this release by the Company,. These shares cannot be sold in the open market for an extended period of time.  The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.